Using an unbiased approach, this important study discovered a role of Ezh2 in the differentiation of granule neuron precursors, the cell of origin for Shh group of medulloblastoma. Furthermore, the ...

Forward steps are being made in HNSCC, and the first patient with MDS has been treated with iadademstat/azacitidine.

新闻稿指出，Camizestrant 是首个且唯一一个新一代口服 SERD 和完全 ER 降解，与广受认可的 CDK4/6 抑制剂联合使用可在一线治疗中带来益处。 值得一提 ...

Camizestrant combined with CDK4/6 inhibitors improved progression-free survival in HR+/HER2- advanced breast cancer with ESR1 mutations in the SERENA-6 trial. In the phase 3 SERENA-6 trial ...

possibly in combination with trastuzumab antibody-drug conjugates, such as trastuzumab emtansine CDK4/6 inhibitors are a more recent treatment option to prevent cancer cell growth and include the ...

This agent, known as Sabatolimab, has been evaluated with an anti-PD-1 antibody known as spartaliuzmab in a phase 1 trial for determining safety profiles and tolerability. (2) Case Study: PARP ...

Medscape, December 20, 2024 SABCS 2024 HRQOL the Same With CDK4/6 Inhibitors in 1st or 2nd Line An analysis of secondary outcomes in the SONIA trial showed that adverse events with CDK4/6 ...

The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib is an emerging cancer therapeutic that just recently gained Food and Drug Administration approval for treatment of estrogen receptor ...

Polydatin, an active ingredient from the roots of Polygonum cuspidatum, is considered to have protective effects on the cardiovascular system and liver. In this study, we demonstrated that polydatin ...